跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

Y0000361

系统适用性试验用环孢素

European Pharmacopoeia (EP) Reference Standard

别名:

环孢菌素A, 抗生素S 7481F1, 环孢霉素

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C62H111N11O12
CAS号:
59865-13-3
分子量:
1202.61
Beilstein:
3647785
MDL编号:
MFCD00274558
UNSPSC代码:
41116107
PubChem化学物质编号:
329830917
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

ciclosporin

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C

InChI

1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1

InChI key

PMATZTZNYRCHOR-CGLBZJNRSA-N

基因信息

human ... PPIA(5478)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Ciclosporin for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

一种具有强大的免疫抑制特性的真菌代谢物。它通过形成抑制钙调神经磷酸酶（蛋白磷酸酶 2B）的环孢菌素A−亲环蛋白复合物来抑制 T 细胞受体的信号转导途径。抑制由白介素1α、脂多糖和TNFα诱导的一氧化氮合成。阻止线粒体释放细胞色素 c。
强效免疫抑制剂；抑制由白介素1α、脂多糖和TNFα诱导的一氧化氮合成；阻止线粒体释放细胞色素 c。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Health hazardExclamation mark
GHS08,GHS07

警示用语：

Danger

危险声明

H302,H350,H360FD

危险分类

Acute Tox. 4 Oral - Carc. 1B - Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Marcel B M Teunissen et al.
The Journal of investigative dermatology, 134(12), 2898-2907 (2014-06-20)
IL-17A is pivotal in the etiology of psoriasis, and CD8(+) T cells with the ability to produce this cytokine (Tc17 cells) are over-represented in psoriatic lesions. Here we demonstrate that the frequency of Tc17 cells in peripheral blood of psoriasis
Anne I Dipchand et al.
Pediatric transplantation, 18(7), 764-770 (2014-08-15)
Cardiac remodeling is associated with plasma biomarkers of fibrinogenesis, inflammation, and oxidative stress, and upregulation of mitogenic, pro-fibrotic, and apoptotic signaling pathways. Our primary objective was to evaluate biomarker and subcellular myocardial changes in pediatric heart transplant recipients. Fifty-two-week prospective
Yasuo Morishima et al.
Blood, 125(7), 1189-1197 (2014-12-19)
We hypothesized that the compatibility of each HLA loci between donor and patient induced divergent transplant-related immunologic responses, which attributed to the individualized manifestation of clinical outcomes. Here, we analyzed 7898 Japanese pairs transplanted with T-cell-replete marrow from an unrelated
Angela C Webster et al.
BMJ (Clinical research ed.), 331(7520), 810-810 (2005-09-15)
To compare the positive and negative effects of tacrolimus and ciclosporin as initial treatment for renal transplant recipients. Systematic review. Reports of comparative randomised trials of tacrolimus and ciclosporin identified by searches of Medline, Embase, the Cochrane Register of Controlled
K J Tinckam et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 15(2), 417-426 (2015-01-24)
Donor-specific HLA antibodies (DSA) have an adverse effect on short-term and long-term lung transplant outcomes. We implemented a perioperative strategy to treat DSA-positive recipients, leading to equivalent rejection and graft survival outcomes. Pretransplant DSA were identified to HLA-A, B, C
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门